Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database

The overall safety profile was largely consistent with clinical trial findings, while newly detected AEs suggest possible rare or delayed toxicities in broader patient populations. These results highlight the importance of continuous post-marketing surveillance and support the need for prospective studies to clarify causal relationships.